Application 091656

Type
ANDA
Sponsor
CADILA PHARMS LTD

Application Products#

Product, Drug, Ingredient table
ProductDrugIngredientFormStrengthReference drugReference standard
001OFLOXACINOFLOXACINTABLET;ORAL200MGNoNo
002OFLOXACINOFLOXACINTABLET;ORAL300MGNoNo
003OFLOXACINOFLOXACINTABLET;ORAL400MGNoNo

Orange Book products#

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A091656-001OFLOXACINOFLOXACIN200MGTABLET / ORALAB2014-09-18
A091656-002OFLOXACINOFLOXACIN300MGTABLET / ORALAB2014-09-18
A091656-003OFLOXACINOFLOXACIN400MGTABLET / ORALAB2014-09-18

Therapeutic equivalence codes#

Application-product, TE code table
Application-productTE code
A091656-001AB
A091656-002AB
A091656-003AB

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
OFLOXACINOFLOXACINModavar Pharmaceuticals LLC93ed9f70-b44f-496b-bdfc-c1bd5f1c260b2026-06-06Boxed warning, Warnings, Adverse reactionsExact identifier
OFLOXACINOFLOXACINCadila Pharmaceuticals Limitedc677b35c-0432-4ee5-af57-1f95449c48b62024-09-12Boxed warning, Warnings, Adverse reactionsExact identifier
OFLOXACINOFLOXACINNivagen Pharmaceuticals, Inc.1779c568-d7bb-4bd5-bc29-13bd52ba8a0a2023-07-26Boxed warning, Warnings, Adverse reactionsExact identifier
OFLOXACINOFLOXACINNivagen Pharmaceuticals, Inc.ee1bf431-97fa-4aba-9cc3-0cfcea779ca22022-02-15Boxed warning, Warnings, Adverse reactionsExact identifier

Boxed warning cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

boxed warning

WARNING SERIOUS ADVERSE REACTIONS INCLUDING TENDINITIS, TENDON RUPTURE, PERIPHERAL NEUROPATHY, CENTRAL NERVOUS SYSTEM EFFECTS AND EXACERBATION OF MYASTHENIA GRAVIS Fluoroquinolones, including ofloxacin, have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together, including: • Tendinitis and tendon rupture • Peripheral neuropathy • Central nervous system effects (see WARNINGS ). Discontinue ofloxacin immediately and avoid the use of fluoroquinolones, including ofloxacin, in patients who experience any of these serious adverse reactions (see WARNINGS). • Fluoroquinolones, including ofloxacin, may exacerbate muscle weakness in persons with myasthenia gravis. Avoid ofloxacin in patients with a known history of myasthenia gravis (See WARNINGS). •Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see WARNINGS), reserve ofloxacin for use in patients who have no alternative treatment options for the following indications: o Acute exacerbation of chronic bronchitis o Uncomplicated cystitis (see INDICATIONS and USAGE )

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

warnings

WARNINGS Disabling and Potentially Irreversible Serious Adverse Reactions Including Tendinitis and Tendon Rupture, Peripheral Neuropathy, and Central Nervous System Effects Fluoroquinolones, including ofloxacin, have been associated with disabling and potentially irreversible serious adverse reactions from different body systems that can occur together in the same patient. Commonly seen adverse reactions include tendinitis, tendon rupture, arthralgia, myalgia, peripheral neuropathy, and central nervous system effects (hallucinations, anxiety, depression, insomnia, severe headaches, and confusion). These reactions can occur within hours to weeks after starting ofloxacin. Patients of any age or without pre-existing risk factors have experienced these adverse reactions (see Warnings ) Discontinue ofloxacin immediately at the first signs or symptoms of any serious adverse reaction. In addition, avoid the use of fluoroquinolones, including ofloxacin, in patients who have experienced any of these serious adverse reactions associated with fluoroquinolones. Tendinitis and Tendon Rupture Fluoroquinolones, including ofloxacin, have been associated with an increased risk of tendinitis and tendon rupture in all ages. This adverse reaction most frequently involves the Achilles tendon, and rupture of the Achilles tendon and has been reported with the rotator cuff (the shoulder), the hand, the biceps, the thumb, and other tendons. Tendinitis or tendon rupture can occur within hours or days of starting ofloxacin, or as long as several months after completion of fluoroquinolone therapy. Tendinitis and tendon rupture can occur bilaterally. The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. Other factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis. Tendinitis and tendon rupture have been reported in patients taking fluoroquinolones who do not have the above risk factors. Discontinue ofloxacin immediately if the patient experiences pain, swelling, inflammation or rupture of a tendon. Avoid fluoroquinolones, including ofloxacin, in patients who have a history of tendon disorders or hav...

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

adverse reactions

ADVERSE REACTIONS The following is a compilation of the data for ofloxacin based on clinical experience with both the oral and intravenous formulations. The incidence of drug-related adverse reactions in patients during Phase 2 and 3 clinical trials was 11%. Among patients receiving multiple-dose therapy, 4% discontinued ofloxacin due to adverse experiences. In clinical trials, the following events were considered likely to be drug-related in patients receiving multiple doses of ofloxacin: nausea 3%, insomnia 3%, headache 1%, dizziness 1%, diarrhea 1%, vomiting 1%, rash 1%, pruritus 1%, external genital pruritus in women 1%, vaginitis 1%, dysgeusia 1%. In clinical trials, the most frequently reported adverse events, regardless of relationship to drug, were: nausea 10%, headache 9%, insomnia 7%, external genital pruritus in women 6%, dizziness 5%, vaginitis 5%, diarrhea 4%, vomiting 4%. In clinical trials, the following events, regardless of relationship to drug, occurred in 1 to 3% of patients: abdominal pain and cramps, chest pain, decreased appetite, dry mouth, dysgeusia, fatigue, flatulence, gastrointestinal distress, nervousness, pharyngitis, pruritus, fever, rash, sleep disorders, somnolence, trunk pain, vaginal discharge, visual disturbances, and constipation. Additional events, occurring in clinical trials at a rate of less than 1%, regardless of relationship to drug, were: Body as a Whole: asthenia, chills, malaise, extremity pain, pain, epistaxis Cardiovascular System: cardiac arrest, edema, hypertension, hypotension, palpitations, vasodilation Gastrointestinal System: dyspepsia Genital/Reproductive System: burning, irritation, pain and rash of the female genitalia; dysmenorrhea; menorrhagia; metrorrhagia Musculoskeletal System: arthralgia, myalgia Nervous System: seizures, anxiety, cognitive change, depression, dream abnormality, euphoria, hallucinations, paresthesia, syncope, vertigo, tremor, confusion Nutritional/Metabolic: thirst, weight loss Respiratory System: respiratory arrest, cough, rhinorrhea Skin/Hypersensitivity: angioedema, diaphoresis, urticaria, vasculitis Special Senses: decreased hearing acuity, tinnitus, photophobia Urinary System: dysuria, urinary frequency, urinary retention The following laboratory abnormalities appeared in ≥ 1% of patients receiving multiple doses of ofloxacin. It is not known whether these abnormalities we...

adverse reactions table

Body as a Whole:asthenia, chills, malaise, extremity pain, pain, epistaxis Cardiovascular System: cardiac arrest, edema, hypertension, hypotension, palpitations, vasodilation Gastrointestinal System: dyspepsia Genital/Reproductive System: burning, irritation, pain and rash of the female genitalia; dysmenorrhea; menorrhagia; metrorrhagia Musculoskeletal System: arthralgia, myalgia Nervous System: seizures, anxiety, cognitive change, depression, dream abnormality, euphoria, hallucinations, paresthesia, syncope, vertigo, tremor, confusion Nutritional/Metabolic: thirst, weight loss Respiratory System: respiratory arrest, cough, rhinorrhea Skin/Hypersensitivity: angioedema, diaphoresis, urticaria, vasculitis Special Senses: decreased hearing acuity, tinnitus, photophobia Urinary System: dysuria, urinary frequency, urinary retention

NDC Listings For This Application#

NDC, Name, Nonproprietary name table
NDCNameNonproprietary nameLabelerMarketing categoryStatus
71209-097OFLOXACINOFLOXACINCadila Pharmaceuticals LimitedANDACurrent
71209-097OFLOXACINOFLOXACINCadila Pharmaceuticals LimitedANDACurrent
71209-097OFLOXACINOFLOXACINCadila Pharmaceuticals LimitedANDACurrent
71209-097OFLOXACINOFLOXACINCadila Pharmaceuticals LimitedANDACurrent
71209-098OFLOXACINOFLOXACINCadila Pharmaceuticals LimitedANDACurrent
71209-098OFLOXACINOFLOXACINCadila Pharmaceuticals LimitedANDACurrent
71209-098OFLOXACINOFLOXACINCadila Pharmaceuticals LimitedANDACurrent
71209-098OFLOXACINOFLOXACINCadila Pharmaceuticals LimitedANDACurrent
71209-099OFLOXACINOFLOXACINCadila Pharmaceuticals LimitedANDACurrent
71209-099OFLOXACINOFLOXACINCadila Pharmaceuticals LimitedANDACurrent
71209-099OFLOXACINOFLOXACINCadila Pharmaceuticals LimitedANDACurrent
71209-099OFLOXACINOFLOXACINCadila Pharmaceuticals LimitedANDACurrent
75834-112OFLOXACINOFLOXACINNivagen Pharmaceuticals, Inc.ANDACurrent
75834-112OFLOXACINOFLOXACINNivagen Pharmaceuticals, Inc.ANDACurrent
75834-112OFLOXACINOFLOXACINNivagen Pharmaceuticals, Inc.ANDACurrent
75834-119OFLOXACINOFLOXACINNivagen Pharmaceuticals, Inc.ANDACurrent
75834-119OFLOXACINOFLOXACINNivagen Pharmaceuticals, Inc.ANDACurrent
75834-119OFLOXACINOFLOXACINNivagen Pharmaceuticals, Inc.ANDACurrent
75834-120OFLOXACINOFLOXACINNivagen Pharmaceuticals, Inc.ANDACurrent
75834-120OFLOXACINOFLOXACINNivagen Pharmaceuticals, Inc.ANDACurrent
75834-120OFLOXACINOFLOXACINNivagen Pharmaceuticals, Inc.ANDACurrent
75834-199OFLOXACINOFLOXACINNivagen Pharmaceuticals, Inc.ANDACurrent
75834-200OFLOXACINOFLOXACINNivagen Pharmaceuticals, Inc.ANDACurrent
75834-201OFLOXACINOFLOXACINNivagen Pharmaceuticals, Inc.ANDACurrent